Which flu shot works best for seniors? new study aims to find out

NCT ID NCT02872311

Completed Knowledge-focused Sponsor: Marshfield Clinic Research Foundation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how well different licensed flu vaccines trigger an immune response in adults aged 65 to 74. About 179 participants received one of four flu vaccines over two flu seasons, and researchers measured their antibody levels at several time points. The goal was to see which vaccine type provides the strongest and longest-lasting immune protection in this age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Influenza vaccines (high-dose, adjuvanted, standard-dose, and recombinant)
What this could lead to: If successful, this could help doctors choose the most effective flu vaccine for older adults, potentially reducing flu-related hospitalizations.
What could go wrong: This is a small, completed study that only measures immune response, not actual prevention of flu illness. Results may not apply to all older adults or other flu seasons.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE RESPONSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE RESPONSE

Contacts and locations

Locations

Marshfield Clinic - Marshfield Center

Marshfield, Wisconsin, 54449, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.